BACKGROUND: Upper extremity lymphedema is a well-described complication of breast cancer treatment. Risk factors for lymphedema development include axillary lymph node dissection (ALND), obesity, increasing age, radiation, and postoperative complications. In this study, we seek to evaluate a cohort of patients who have either self-referred or been referred to the Department of Physical Therapy for lymphedema treatment. Our goal is to evaluate specific risk factors associated with the severity of lymphedema in this patient population. METHODS: All patients who presented to the Wexner Medical Center at the Ohio State University between January 1, 2009, and December 31, 2010, with a chief complaint of upper extremity lymphedema after breast cancer treatment were reviewed retrospectively. Upper extremity lymphedema index (UELI) was used as a severity indicator and patient factors including demographics and breast cancer treatments were evaluated. Univariate and multivariate statistical analyses were performed. RESULTS: Fifty (4.5%) patients presented for upper extremity lymphedema treatment after breast cancer treatment (total of 1106 patients treated surgically for breast cancer). Greater UELIs were found in patients 50 years and older, those with ALND, radiation, chemotherapy, pathologic stage greater than 3, and an International Society of Lymphology lymphedema stage II (P < 0.05). The multivariate model showed age older than 50 years and pathologic stage greater than 3 were significant predictors of higher UELI (P < 0.05). CONCLUSIONS: In this study, we report that in patients who present for lymphedema treatment, increased UELI is significantly related to ALND, radiation therapy, chemotherapy, age, and pathologic stage. An improved understanding of the patient population referred for lymphedema treatment will allow for the identification of patients who may be candidates for therapeutic intervention.
BACKGROUND:Upper extremity lymphedema is a well-described complication of breast cancer treatment. Risk factors for lymphedema development include axillary lymph node dissection (ALND), obesity, increasing age, radiation, and postoperative complications. In this study, we seek to evaluate a cohort of patients who have either self-referred or been referred to the Department of Physical Therapy for lymphedema treatment. Our goal is to evaluate specific risk factors associated with the severity of lymphedema in this patient population. METHODS: All patients who presented to the Wexner Medical Center at the Ohio State University between January 1, 2009, and December 31, 2010, with a chief complaint of upper extremity lymphedema after breast cancer treatment were reviewed retrospectively. Upper extremity lymphedema index (UELI) was used as a severity indicator and patient factors including demographics and breast cancer treatments were evaluated. Univariate and multivariate statistical analyses were performed. RESULTS: Fifty (4.5%) patients presented for upper extremity lymphedema treatment after breast cancer treatment (total of 1106 patients treated surgically for breast cancer). Greater UELIs were found in patients 50 years and older, those with ALND, radiation, chemotherapy, pathologic stage greater than 3, and an International Society of Lymphology lymphedema stage II (P < 0.05). The multivariate model showed age older than 50 years and pathologic stage greater than 3 were significant predictors of higher UELI (P < 0.05). CONCLUSIONS: In this study, we report that in patients who present for lymphedema treatment, increased UELI is significantly related to ALND, radiation therapy, chemotherapy, age, and pathologic stage. An improved understanding of the patient population referred for lymphedema treatment will allow for the identification of patients who may be candidates for therapeutic intervention.
Authors: Muhammad Asim; Alvin Cham; Sharmana Banerjee; Rachael Nancekivell; Gaelle Dutu; Catherine McBride; Shelley Cavanagh; Ross Lawrenson; Ian Campbell Journal: N Z Med J Date: 2012-03-09
Authors: Lee Gravatt Wilke; Linda M McCall; Katherine E Posther; Pat W Whitworth; Douglas S Reintgen; A Marilyn Leitch; Sheryl G A Gabram; Anthony Lucci; Charles E Cox; Kelly K Hunt; James E Herndon; Armando E Giuliano Journal: Ann Surg Oncol Date: 2006-03-02 Impact factor: 5.344
Authors: Ana Paula de Melo Ferreira; Elyonara Mello de Figueiredo; Renilton Aires Lima; Eduardo Batista Cândido; Marilene Vale de Castro Monteiro; Telma Maria Rossi de Figueiredo Franco; Paulo Traiman; Agnaldo Lopes da Silva-Filho Journal: Eur J Obstet Gynecol Reprod Biol Date: 2012-07-15 Impact factor: 2.435
Authors: Umberto Veronesi; Giovanni Paganelli; Giuseppe Viale; Alberto Luini; Stefano Zurrida; Viviana Galimberti; Mattia Intra; Paolo Veronesi; Chris Robertson; Patrick Maisonneuve; Giuseppe Renne; Concetta De Cicco; Francesca De Lucia; Roberto Gennari Journal: N Engl J Med Date: 2003-08-07 Impact factor: 91.245
Authors: Antonio J Forte; Andrea Sisti; Maria T Huayllani; Daniel Boczar; Gabriela Cinotto; Pedro Ciudad; Oscar J Manrique; Xiaona Lu; Sarah McLaughlin Journal: Gland Surg Date: 2020-04
Authors: Chantal M Ferguson; Meyha N Swaroop; Nora Horick; Melissa N Skolny; Cynthia L Miller; Lauren S Jammallo; Cheryl Brunelle; Jean A O'Toole; Laura Salama; Michelle C Specht; Alphonse G Taghian Journal: J Clin Oncol Date: 2015-12-07 Impact factor: 44.544
Authors: Brigid K Killelea; Jessica B Long; Weixiong Dang; Sarah S Mougalian; Suzanne B Evans; Cary P Gross; Shi-Yi Wang Journal: Ann Surg Oncol Date: 2018-03-07 Impact factor: 5.344
Authors: Joost Wolfs; Jop Beugels; Merel Kimman; Andrzej A Piatkowski de Grzymala; Esther Heuts; Xavier Keuter; Hanneke Tielemans; Dietmar Ulrich; R van der Hulst; Shan Shan Qiu Journal: BMJ Open Date: 2020-01-15 Impact factor: 2.692